<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30092555</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>24</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>24</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-1967</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>69</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer treatment reviews</Title>                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>            </Journal>            <ArticleTitle>Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>204-214</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(18)30132-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2018.07.013</ELocationID>            <Abstract>                <AbstractText>Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) disease. Advances in treating this type of MBC have focused on improving the efficacy of endocrine therapy by adding agents that target specific molecular pathways of breast cancer cell growth and survival. The combination of the aromatase inhibitor exemestane and the mammalian target of rapamycin inhibitor, everolimus, more than doubled median progression-free survival compared with exemestane alone (7.8 vs 3.2 months, respectively; hazard ratio 0.45 [95% confidence interval 0.38-0.54]; log rank P &lt; 0.0001) in the BOLERO-2 study in postmenopausal women with HR+, HER2- locally advanced or metastatic breast cancer that had recurred or progressed on prior non-steroidal aromatase inhibitor therapy. In addition, everolimus plus exemestane was associated with a manageable safety profile. The results of BOLERO-2 led to regulatory approval of everolimus plus exemestane. Additional everolimus-based combinations have been or are under investigation in the HR+, HER2- MBC setting, including combinations with letrozole, fulvestrant, ribociclib, tamoxifen, and chemotherapy. This review summarizes key data on everolimus-based combinations focusing on efficacy, safety, biomarkers, quality of life, and health economic outcomes. These data are discussed in the context of the changing MBC treatment algorithm to provide insights into the clinical relevance of everolimus-based combinations.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>O'Shaughnessy</LastName>                    <ForeName>Joyce</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Baylor University Medical Center, Texas Oncology, US Oncology, 3410 Worth St, Suite 400, Dallas, TX 75246, USA. Electronic address: joyce.oshaughnessy@usoncology.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thaddeus Beck</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Highlands Oncology Group, 3232 N Northhills Blvd, Fayetteville, AR 72703, USA. Electronic address: TBeck@hogonc.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Royce</LastName>                    <ForeName>Melanie</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>University of New Mexico Comprehensive Cancer Center, 7605 Via de Calma NE, Albuquerque, NM 87113, USA. Electronic address: mroyce@mroycemdphd.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Cancer Treat Rev</MedlineTA>            <NlmUniqueID>7502030</NlmUniqueID>            <ISSNLinking>0305-7372</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>094ZI81Y45</RegistryNumber>                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>9HW64Q8G6G</RegistryNumber>                <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>NY22HMQ4BX</RegistryNumber>                <NameOfSubstance UI="C056516">exemestane</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>W36ZG6FT64</RegistryNumber>                <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Endocrine therapy</Keyword>            <Keyword MajorTopicYN="N">Everolimus</Keyword>            <Keyword MajorTopicYN="N">Hormone receptor-positive</Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30092555</ArticleId>            <ArticleId IdType="pii">S0305-7372(18)30132-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.ctrv.2018.07.013</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>